{"organizations": [], "uuid": "2fdf1284a7895371dfbda8d438aa4f0e5f3ccf59", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180213.html", "section_title": "Archive News &amp; Video for Tuesday, 13 Feb 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-tamarkin-medical-reports-73-percen/brief-tamarkin-medical-reports-7-3-percent-passive-stake-in-foamix-pharmaceuticals-idUSFWN1Q31EM", "country": "US", "domain_rank": 408, "title": "Tamarkin Medical Reports 7.3 Percent Passive Stake In Foamix Pharmaceuticals", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.033, "site_type": "news", "published": "2018-02-14T06:24:00.000+02:00", "replies_count": 0, "uuid": "2fdf1284a7895371dfbda8d438aa4f0e5f3ccf59"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-tamarkin-medical-reports-73-percen/brief-tamarkin-medical-reports-7-3-percent-passive-stake-in-foamix-pharmaceuticals-idUSFWN1Q31EM", "ord_in_thread": 0, "title": "Tamarkin Medical Reports 7.3 Percent Passive Stake In Foamix Pharmaceuticals", "locations": [], "entities": {"persons": [], "locations": [{"name": "foamix", "sentiment": "none"}], "organizations": [{"name": "foamix pharmaceuticals", "sentiment": "negative"}, {"name": "reuters) - foamix pharmaceuticals ltd", "sentiment": "neutral"}, {"name": "sec", "sentiment": "none"}, {"name": "pharmaceuticals", "sentiment": "none"}, {"name": "thomson reuters trust principles", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 13 (Reuters) - Foamix Pharmaceuticals Ltd:\n* TAMARKIN MEDICAL INNOVATIONS LTD REPORTS 7.3 PERCENT PASSIVE STAKE IN FOAMIX PHARMACEUTICALS AS OF DECEMBER 31, 2017 - SEC FILING Source text: ( bit.ly/2so9g8s ) Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html", "http://bit.ly/2so9g8s"], "published": "2018-02-14T06:24:00.000+02:00", "crawled": "2018-02-14T12:43:56.044+02:00", "highlightTitle": ""}